Cytochrome P450 enzymes: a review on drug metabolizing enzyme inhibition studies in drug discovery and development.

Autor:	Rao Gajula SN; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad, Balanagar, Telangana, 50003, India., Pillai MS; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad, Balanagar, Telangana, 50003, India., Samanthula G; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad, Balanagar, Telangana, 50003, India., Sonti R; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad, Balanagar, Telangana, 50003, India.
Jazyk:	angličtina
Zdroj:	Bioanalysis [Bioanalysis] 2021 Sep 14. Date of Electronic Publication: 2021 Sep 14.
DOI:	10.4155/bio-2021-0132
Abstrakt:	Assessment of drug candidate's potential to inhibit cytochrome P450 (CYP) enzymes remains crucial in pharmaceutical drug discovery and development. Both direct and time-dependent inhibition of drug metabolizing CYP enzymes by the concomitant administered drug is the leading cause of drug-drug interactions (DDIs), resulting in the increased toxicity of the victim drug. In this context, pharmaceutical companies have grown increasingly diligent in limiting CYP inhibition liabilities of drug candidates in the early stages and examining risk assessments throughout the drug development process. This review discusses different strategies and decision-making processes for assessing the drug-drug interaction risks by enzyme inhibition and lays particular emphasis on in vitro study designs and interpretation of CYP inhibition data in a stage-appropriate context.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu